Industry Newsbiopharmabriumvitg therapeuticsearnings
TG Therapeutics Posts Strong Q3 Revenue Gains
5.1
Relevance Score
On January 15, Goldman Sachs raised its price target on TG Therapeutics to $39 from $37 while maintaining a Neutral rating after the company disclosed 2026 revenue guidance of $875–$900 million and faster-than-expected Phase 3 enrollment for subcutaneous BRIUMVI. TG reported Q3 2025 revenue of $161.7 million, GAAP net income of $390.9 million, and U.S. BRIUMVI sales of about $153 million.
